Skip to content

Author

T. D. de Gruijl

We have 3 of 506 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

PET pharmacokinetics of [¹⁸F]F-AraG as a marker of T cell activation during immunotherapy with a STING agonist with and without anti-PD-1

There is an urgent need for clinical biomarkers to monitor the mechanistic efficacy of immunotherapy in oncology. The [18F]F-AraG tracer, developed to image activated T cells, may provide the means to establish such a biomarker. This study extends previously reported pharmacokinetic findings in untreated NSCLC across a...

J. E. E. Pouw, M. Stavenga, J. Wijngaarden et al. · 0 citations
Sep 2026

Pre-existing immunity and hrHPV status determine immunotherapy response in advanced penile cancer: biomarkers and overall survival in the PERICLES trial.

Mature overall survival (OS) and updated progression-free survival (PFS) outcomes and an in-depth biomarker analysis are reported and highlighted CD8+PD1+ T-cells as candidate biomarkers in relation to clinical benefit from immune checkpoint blockade in advanced PeSCC.

Tynisha S. Rafael, Alberto Gil-Jimenez, L. Elst et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.